Cited by 59Genetics, Aging, and Longevity in Model OrganismsTelomeres, Telomerase, and SenescenceMetabolism, Diabetes, and Cancer

Molecular pathology endpoints useful for aging studies

Open access
Niedernhofer, L.J., Kirkland, J.L., Ladiges, W.·2017·Ageing Research Reviews

Abstract

The first clinical trial aimed at targeting fundamental processes of aging will soon be launched (TAME: Targeting Aging with Metformin). In its wake is a robust pipeline of therapeutic interventions that have been demonstrated to extend lifespan or healthspan of preclinical models, including rapalogs, antioxidants, anti-inflammatory agents, and senolytics. This ensures that if the TAME trial is successful, numerous additional clinical trials are apt to follow. But a significant impediment to these trials remains the question of what endpoints should be measured? The design of the TAME trial very cleverly skirts around this based on the fact that there are decades of data on metformin in humans, providing unequaled clarity of what endpoints are most likely to yield a positive outcome. But for a new chemical entity, knowing what endpoints to measure remains a formidable challenge. For economy's sake, and to achieve results in a reasonable time frame, surrogate markers of lifespan and healthy aging are desperately needed. This review provides a comprehensive analysis of molecular endpoints that are currently being used as indices of age-related phenomena (e.g., morbidity, frailty, mortality) and proposes an approach for validating and prioritizing these endpoints.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.arr.2016.09.012

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Limitations of current clinical trials include small recruitment sizes, few measurable clinically-relevant outcomes appropriate for older adults, and need for biomarkers tracking pharmacokinetic, pharmacodynamic, and mechanistic properties and serving as surrogate endpoints.

    “Limitations of current clinical trials include small recruitment sizes, the paucity of measurable, clinically-relevant outcomes appropriate for older adults, as well as the need for biomarkers that follow pharmacokinetic, pharmacodynamic, and mechanistic properties of study drugs and could serve as surrogate endpoints [92–94].”

    From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [94]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 95 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Niedernhofer, L. J., Kirkland, J. L., & Ladiges, W.
Affiliations
  • Scripps Research Institute (US)
  • Mayo Clinic (US)
  • University of Washington (US)
Corresponding author
Niedernhofer, L.J.
Venue
Ageing Research Reviews
Publisher
Elsevier BV
Published
2017-05
Volume
35
Pages
241-249
ISSN
1568-1637 (ISSN-L)
OpenAlex
W2530258438
Cited by
59
References
95
Citations by year
2026: 2 · 2025: 5 · 2024: 1 · 2023: 6 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 12
FWCI
0.93
Type
journal article
Language
en
Open access
Locations
  • Ageing Research Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH/NIA (P01 AG043376)
  • Aldabra Biosciences
  • NIH (AG13925, AG044396, DK50456, R24 AG047115)
  • Connor Group
  • the Noaber, Ellison, and Glenn Foundations
  • American Federation for Aging Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
molecular endpoints, aging, healthspan, lifespan extension, metformin, surrogate markers, senolytics, rapalogs, anti-inflammatory agents, antioxidants, frailty, mortality, morbidity, endpoint validation, anti-aging therapeutics
MeSH terms
Aging, Humans, Life Expectancy, Longevity, Biomarkers, Pathology, Molecular

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review